業績

2024年度

  • Kakei Y, Ioroi T, Miyakoda K, Ito T, Kashin M, Shirai T, Hasegawa T, Sakane T, Yano I. Akashi M. Assessment of Patient Characteristics Influencing the Analgesic Effects of Ibuprofen Gargle After Mandibular Third Molar Extractions. Cureus, 16(4): e57516 (2024)
  • Kunimoto Y, Hikasa S, Ishihara M, Tsukiji M, Nobori K, Kimura T, Onishi K, Yamamoto Y, Haruta K, Kasiwabara Y, Fujii K, Fukudo M. Factors associated with incomplete adherence to integrase strand transfer inhibitor-containing single-tablet regimen among Japanese people living with HIV. J Pharm Health Care Sci, 10(1):27 (2024)
  • Hori T, Yamamoto K, Ito T, Ikushima S, Omura T, Yano I. Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer. Investigational New Drugs,42(3): 281-288 (2024)
  • Tomida T, Kimura T, Yamamoto K, Uda A, Matsumoto Y, Tamura N, Iida M, Tanifuji A, Matsumoto K, Mizuta N, Ebisawa K, Ohji G, Omura T, Iwata K, Yano I. Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study. J Pharm Health Care Sci, 10(1):54 (2024)
  • Konishi T, Kitahiro Y, Fujiwara N, Yamamoto K, Hashimoto M, Ito T, Itohara K, Fujioka K, Imafuku H, Otsuka I, Omura T, Yano I. Pharmacokinetics of Brexpiprazole, Quetiapine, Risperidone, and Its Active Metabolite Paliperidone in a Postpartum Woman and Her Baby. Ther Drug Monit, 46(5):687-691 (2024)
  • Kakei Y, Morioka I, Imai T, Itohara K, Yano I, Takahashi N, Yoshikawa T, Moriuchi H, Ito Y, Fujioka K, Oka A. Assessment of patients’ characteristics associated with the efficacy and safety of oral valganciclovir treatment for infants with symptomatic congenital cytomegalovirus disease. J Infect Chemother, 30(10):971-977 (2024)
  • Kurimura T, Omura T, Yamamoto K, Tanaka H, Kimura T, Itohara K, Kitahiro Y, Habu Y, Sakane T, Yano I. Prolonged Prothrombin Time due to Drug-Drug Interaction of Warfarin after the Change from Bosentan to Macitentan: A Case of Pharmacist Intervention in the Outpatient Clinic. Kobe J Med Sci, 70(4): E125-E129 (2025)
  • Takahashi R, Itohara K, Nakagawa S, Katada Y, Sugimoto M, Umemura K, Matsumura K, Hira D, Tsuda M, Katsube Y, Tanaka S, Ohsumi A, Nakajima D, Nagao M, Date H, Terada T. Model-Informed Dosing Optimization of Tacrolimus for Concomitant Administration With Itraconazole to Japanese Lung Transplant Recipients. Ther Drug Monit, 47(2):248-257 (2025)
 

2023年度

  • Tanda M, Yamamoto K, Hori T, Nishiguchi H, Yagi M, Shimizu M, Konishi T, Ozaki T, Yoshioka N, Tachihara M, Ito T, Ikushima S, Omura T, Yano I. Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients. Anticancer Res, 43 (4): 1775-1783 (2023)
  • Mahdy WYB, Yamamoto K, Ito T, Fujiwara N, Fujioka K, Horai T, Otsuka I, Imafuku H, Omura T, Iijima K, Yano I. Physiologically-based pharmacokinetic model to investigate the effect of pregnancy on risperidone and paliperidone pharmacokinetics: Application to a pregnant woman and her neonate. Clin Transl Sci, 16 (4): 618-630 (2023)
  • Fujimoto T, Hyodo Y, Ishimura T, Tashiro Y, Endo T, Nisioka S, Yokoyama N, Yamamoto K, Yano I, Fujisawa M. Association of alpha-actinin-3 polymorphism with sarcopenia in kidney transplant recipients. Transplant Proc, 55 (4): 824-828 (2023)
  • Hori T, Yamamoto K, Ito T, Ikushima S, Omura T, Yano I. Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study. Biol Pharm Bull, 46 (6): 788-795 (2023)
  • Masui S, Yonezawa A, Nakamura M, Onishi A, Hashimoto M, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Yokoyama K, Iwamoto N, Shimada T, Itohara K, Hira D, Nakagawa S, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, Matsubara K. Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis. Biol Pharm Bull, 46 (8): 1112-1119 (2023)
  • Ishihara M, Hikasa S, Tsukiji M, Kunimoto Y, Nobori K, Kimura T, Onishi K, Yamamoto Y, Haruta K, Kashiwabara Y, Fujii K, Shimabukuro S, Watanabe D, Tsurumi H, Suzuki A. Assessment of satisfaction with antiretroviral drugs and the need for long-acting injectable medicines among people living with HIV in Japan and its associated factors: a prospective multicenter cross-sectional observational study. AIDS Res Ther, 20 (1): 62 (2023)
  • Kurimura T, Yamamoto K, Tanaka H, Toba T, Kimura T, Habu Y, Itohara K, Kitahiro Y, Omura T, Yano I. Significance of pharmacist intervention to oral antithrombotic therapy in the pharmaceutical outpatient clinic of cardiovascular internal medicine: a retrospective cohort study. J Pharm Health Care Sci, 9 (1): 28 (2023)
  • Mizutani Y, Kawamoto S, Takahashi M, Doi H, Wakida K, Tabuchi S, Tanda M, Soga A, Chijiki R, Takakura H, Kawaguchi K, Higashime A, Watanabe M, Ichikawa H, Matsumoto S, Sakai R, Goto H, Kurata K, Kakiuchi S, Miyata Y, Uryu K, Inui Y, Kitao A, Yakushijin K, Matsuoka H, Minami H. Efficacy and Safety of Synbiotics in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Randomized, Double-blinded, Placebo-controlled Pilot Study. Intern Med, 62 (20): 2949-2958 (2023)
  • Nakayama Y, Enomoto D, Yamamoto K, Takara K. Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus. Anticancer Res, 43 (10): 4349-4357 (2023)
  • Ioroi T, Kakei Y, Ito T, Shirai T, Okazaki Y, Hasegawa T, Akashi M, Yano I. Efficacy and safety of ibuprofen gargle for postoperative pain after mandibular third molar extraction: A phase II, placebo-controlled, double-blind, randomized crossover trial. Clin Exp Dent Res, 9 (6): 1058-1068 (2023)
  • Katada Y, Nakagawa S, Nagao M, Umemura K, Itohara K, Nishikawa A, Hashi S, Katsube Y, Hira D, Ohsumi A, Nakajima D, Date H, Terada T. Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis. Transpl Infect Dis, 25 (6): e14141 (2023)
  • Tomida T, Itohara K, Yamamoto K, Kimura T, Fujita K, Uda A, Kitahiro Y, Yokoyama N, Hyodo Y, Omura T, Yano I. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatre
  • Nishiguchi H, Omura T, Sato A, Kitahiro Y, Yamamoto K, Kunimasa J, Yano I. Luteolin protects against 6-hydoroxydopamine-induced cell death via an upregulation of HRD1 and SEL1L. Neurochem Res, 49 (1): 117-128 (2024)
  • Kitahiro Y, Yamamoto K, Yakushijin K, Ioroi T, Tanda M, Itohara K, Omura T, Minami H, Yano I. The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial. JMIR Res Protoc, 13: e54882 (2024)
  • Sakaue T, Yamamoto K, Itohara K, Kitahiro Y, Endo T, Yokoyama N, Ishimura T, Omura T, Yano I. Population pharmacokinetics of everolimus in renal transplant recipients receiving long-term multiple immunosuppressive therapy. Drug Metab Pharmacokinet. 56: 101009 (2024)
  • Nishikawa A, Ito I, Yonezawa A, Itohara K, Matsubara T, Sato Y, Matsumura K, Hamada S, Tanabe N, Kai S, Imoto E, Yoshikawa K, Ohtsuru S, Yanagita M, Hirai T, Terada T. Pharmacokinetics of GS-441524, the active metabolite of remdesivir, in patients receiving continuous renal replacement therapy: A case series. J Infect Chemother, 30 (4): 348-351 (2024)
  • Kawata M, Yonezawa A, Mineharu Y, Itohara K, Mizota T, Matsui Y, Kikuchi T, Yamao Y, Hattori EY, Hamada M, Hira D, Furukawa K, Miyamoto S, Terada T, Matsubara K, Arakawa Y. Development of extended pharmacokinetic models for propofol based on measured blood and brain concentrations. Sci Rep, 14 (1): 6326 (2024)
 

2022年度

  • Matsuda Y, Nakagawa S, Yano I, Masuda S, Imai S, Yonezawa A, Yamamoto T,Sugimoto M, Tsuda M, Tsuzuki T, Omura T, Nakagawa T, Chen-Yoshikawa TF,Nagao M, Date H, Matsubara K. Effect of itraconazole and its metabolitehydroxyitraconazole on the blood concentrations of cyclosporine and tacrolimusin lung transplant recipients. Biol Pharm Bull, 45 (4): 397-402 (2022)
  • Kunimitsu Y, Morio K, Hirata S, Yamamoto K, Omura T, Hara T, Harada K,Fujisawa M, Yano I. Effects of proton pump inhibitors on survival prognosisin patients with metastatic or unresectable urothelial carcinoma treatedwith pembrolizumab. Biol Pharm Bull, 45(5): 590-595 (2022)
  • Kakei Y, Ioroi T, Ito T, Okazaki Y, Hasegawa T, Yano I, Akashi M. Efficacy of ibuprofen gargle for postoperative pain after mandibular third molar extraction: protocol for a phase II, placebo-controlled, double-blind, randomized crossover trial. JMIR Res Protoc, 11(5): e35533 (2022)
  • Morio K, Kurata Y, Kawaguchi-Sakita N, Shiroshita A, Kataoka Y. Efficacyof Metformin in Patients with Breast Cancer Receiving Chemotherapy or EndocrineTherapy: Systematic Review and Meta-analysis. Ann Pharmacother, 56(3):245-255 (2022)
  • Kimura T, Fujita M, Shimizu M, Sumiyoshi K, Bansho S, Yamamoto K, OmuraT, Yano I. Effectiveness of pharmacist intervention for deprescribing potentiallyinappropriate medications: a prospective observational study. J Pharm HealthCare Sci, 8:12 (2022)
  • Katada Y, Nakagawa S, Itohara K, Suzuki T, Kato R, Endo H, Sugimoto M, Yonezawa A, Nakagawa T, Ohsumi A, Nakajima D, Date H, Terada T. Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation. J Pharm Health Care Sci, 8:25 (2022)
  • Takaichi M, Osawa K, Nomoto R, Nakanishi N, Kameoka M, Miura M, ShigemuraK, Kinoshita S, Kitagawa K, Uda A, Miyara T, Mertaniasih NM, Hadi U, RaharjoD, Yulistiani R, Fujisawa K, Kuntaman K, Shirakawa T. Antibiotic resistancein non-typhoidal Salmonella enterica strains isolated from chicken meatin Indonesia. Pathogens, 11(5): 543 (2022)
  • Yamamoto K, Ioroi T, Shinomiya K, Yoshida A, Harada K, Fujisawa M, OmuraT, Ikemi Y, Nakagawa S, Yonezawa A, Ogawa O, Matsubara K, Iwamoto T, NishikawaK, Hayashi S, Tohara D, Murakami Y, Motoshima T, Jono H, Yano I. STAT3polymorphism associates with mTOR inhibitor-induced interstitial lung diseasein patients with renal cell carcinoma. Oncol Res, 29(1):11-23 (2022)
  • Yamamoto K, Nishiyama S, Kunisada M, Iida M, Ito T, Ioroi T, Makimoto H, Omura T, Harada K, Fujisawa M, Nishigori C, Yano I. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II study (DGA study). Oncologist, 27(5): e384-e392 (2022)
  • Shigetsura Y, Imai S, Endo H, Shimizu Y, Ueda K, Murai T, Itohara K, NakagawaS, Yonezawa A, Ikemi Y, Fukatsu S, Kitada N, Terada T, Nakagawa T, MatsubaraK. Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepinesfor Treating Insomnia in Patients With Major Depressive Disorder. ClinNeuropharmacol, 45(3): 52-60 (2022)
  • Masui S, Yonezawa A, Yokoyama K, Iwamoto N, Shimada T, Onishi A, OnizawaH, Fujii T, Murakami K, Murata K, Tanaka M, Nakagawa S, Hira D, ItoharaK, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, MatsubaraK. N-terminus of Etanercept is Proteolytically Processed by DipeptidylPeptidase-4. Pharm Res, 39(10): 2541-2554 (2022)
  • Ogihara T, Kagawa M, Yamanaka R, Imai S, Itohara K, Hira D, Nakagawa S, Yonezawa A, Ito M, Nakagawa T, Terada T, Matsubara K. Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis. J Nat Med, 77(1): 53-63 (2022)
  • Itohara K, Yano I, Nakagawa S, Sugimoto M, Hirai M, Yonezawa A, Imai S,Nakagawa T, Hira D, Ito T, Hata K, Hatano E, Terada T, Matsubara K. Populationpharmacokinetics of everolimus in adult liver transplant patients: Comparisonto tacrolimus disposition and extrapolation to pediatrics. Clin TranslSci, 15(11): 2652-2662 (2022)
  • Ikuta K, Nakagawa S, Yamawaki C, Itohara K, Hira D, Imai S, Yonezawa A,Nakagawa T, Sakuragi M, Sato N, Uchino E, Yanagita M, Terada T. Use ofproton pump inhibitors and macrolide antibiotics and risk of acute kidneyinjury: a self-controlled case series study. BMC Nephrol, 23(1): 383 (2022)
  • Nakagawa S, Shimazaki A, Funakoshi T, Yonezawa A, Kataoka S, Horimatsu T, Hira D, Itohara K, Imai S, Nakagawa T, Matsubara T, Yanagita M, Muto M, Matsubara K, Terada T. Effect of Severe Renal Dysfunction on the Plasma Levels of DNA-Reactive Platinum after Oxaliplatin Administration. Biol Pharm Bull, 46(2): 194-200 (2023)
  • Kitahiro Y, Ioroi K, Kakei Y, Yamashita J, Kimoto A, Hasegawa T, MoriokaA, Yamamoto K, Akashi M, Yano I. Efficacy and Long-Term Safety of IbuprofenGargle for Oral Lichen Planus: A Study Protocol of Randomized Crossoverand Long-Term Extension Trials. Methods Protoc, 6(7): 1-11 (2023)
  • Enomoto D, Yamamoto K, Matsumoto Y, Morioka A, Omura T, Komatsu S, YanoY, Fukumoto T, Yano I. ALBI grade is a predictive factor of lenvatinibtreatment discontinuation due to adverse events in hepatocellular carcinoma.Anticancer Res, 43(3): 1317-1323 (2023)
 

2021年度

  • Saito J, Nadatani N, Setoguchi M, Nakao M, Kimura H, Sameshima M, KobayashiK, Matsumoto H, Yoshikawa N, Yokoyama T, Takahashi H, Suenaga M, WatanabeR, Imai K, Obara M, Hashimoto M, Yamamoto K, Fujiwara N, Sakata W, NagaiH, Enokihara T, Katayama S, Takahashi Y, Araki M, Iino K, Akiyama N, KatsuH, Fushimi K, Takeda T, Torimoto M, Kishi R, Mitsuya N, Kihara R, HasegawaY, Hamada Y, Kimura T, Wada M, Tanzawa A, Yamatani A. Potentially harmfulexcipients in neonatal medications: a multicenter nationwide observationalstudy in Japan. J Pharm Health Care Sci, 7(1):23 (2021)
  • Koyanagi M, Imai S, Matsumoto M, Iguma Y, Kawaguchi-Sakita, N, Kotake T, Iwamitsu Y, Ntogwa M, Hiraiwa R, Nagayasu K, Saigo M, Ogihara T, Yonezawa A, Omura T, Nakagawa S, Nakagawa T, Matsubara K. Pro-nociceptive roles of Schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy. Cancer Res, 81(8): 2207-2219 (2021)
  • Nakayama Y, Takara K, Minegaki T, Yamamoto K, Omura T, Yano I. Inductionof Cross-resistance to ABCB1 Substrates in Venetoclax-resistant Human LeukemiaHL60 Cells. Anticancer Res, 41(9):4239-4248 (2021)
  • Uda A, Shigemura K, Kitagawa K, Osawa K, Kusuki Mari, Yan Y, Yano I, MiyaraT. Effect of Antimicrobial Stewardship on Oral Quinolone Use and ResistancePatterns over 8 Years (2013-2020). Antibiotics, 10(11):1426 (2021)
  • Itohara K, Yano I, Nakagawa S, Yonezawa A, Omura T, Imai S, Nakagawa T, Sawada A, Kobayashi T, Tochio A, Sakai K, Taura K, Ogawa O, Matsubara K. Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients. Drug Metab Pharmacokinet, 42(2):100423 (2022)
  • Ito T, Yamamoto K, Furukawa J, Harada K, Fujisawa M, Omura T, Yano I. Associationof sunitinib concentration and clinical outcome in patients with metastaticrenal cell carcinoma treated with a 2-week-on and 1-week-off schedule.J Clin Pharm Ther, 47(1):81-88 (2022)
  • Onishi R, Shigemura K, Osawa K, Yang Y, Maeda K, Fang S, Sung S, OnumaK, Uda A, Miyara T, Fujisawa M. The Antimicrobial Resistance Characteristicsof Imipenem-Non-Susceptible, Imipenemase-6-Producing Escherichia coli.Antibiotics, 11(1):32 (2022)
  • Uda A, Ebisawa K, Sakon H, Kusuki M, Izuta R, Yahata M, Yano I, Miyara T. Sustained Improvements in Antimicrobial Therapy and Clinical Outcomes Following a Pharmacist-Led Antimicrobial Stewardship Intervention: Uncontrolled Before-After Study. J Clin Med, 11(3):566 (2022)
  • Uda A, Onuma K, Shigemura K, Kitagawa K, Yan Y, Osawa K, Yano I, MiyaraT. Impact of Cefazolin Shortage on Clinical Outcomes of Adult Patientswith Bacteremia Caused by Methicillin-Susceptible Staphylococcus aureusin a Tertiary Care University Hospital. Antibiotics, 10(10):1247 (2022)
  • Omura T, Nomura L, Watanabe R, Nishiguchi H, Yamamoto K, Imai S, NakagawaS, Itohara K, Yonezawa A, Nakagawa T, Kunimasa J, Yano I, Matsubara K.MicroRNA-101 Regulates 6-Hydroxydopamine-Induced Cell Death by TargetingSuppressor/Enhancer Lin-12-Like in SH-SY5Y Cells. Front Mol Neurosci, 14(748026)(2022)
 

2020年度

  • Jin C, Yonezawa A, Yoshimatsu H, Imai S, Koyanagi M, Yamanishi K, Nakagawa S, Itohara K, Omura T, Nakagawa T, Nagai J, Matsubara K. Effect of riboflavin deficiency on development of the cerebral cortex in Slc52a3 knockout mice. Sci Rep, 10(1):18443 (2020)
  • Ioroi T, Kiyota N, Imamura Y, Tanda M, Aoki S, Okuno M, Yamamoto K, SasakiR, Nibu K, Minami H, Hirai M, Yano I. Ibuprofen Gargle for Chemo- or Chemoradiotherapy-InducedOral Mucositis: A Feasibility Study. J Pharm Health Care Sci, 6:12 (2020)
  • Yamashita K, Ogihara T, Hayashi M, Nakagawa T, Ishizaki Y, Kume M, YanoI, Niigata R, Hiraoka J, Yasui H, Nakamura T. Association between dexamethasonetreatment and alterations in serum concentrations of trace metals. Pharmazie,75(5): 218-222 (2020)
  • Ito T, Yamamoto K, Ogawa S, Furukawa J, Harada K, Fujisawa M, Omura T, Yano I. Model-based assessment of pharmacokinetic changes of sunitinib, tacrolimus, and everolimus in a patient with metastatic renal cell carcinoma after renal transplantation. Drug Metab Pharmacokinet, 35(5):405-409 (2020)
  • Kondo M, Nakagawa S, Orii S, Itohara K, Sugimoto M, Omura T, Sato Y, ImaiS, Yonezawa A, Nakagawa T, Matsubara K. Share Association of Initial TroughConcentrations of Vancomycin with Outcomes in Pediatric Patients with Gram-Positive Bacterial Infection. Biol Pharm Bull. 43(10):1463-1468 (2020)
  • Ntogwa M, Imai S, Hiraiwa R, Koyanagi M, Matsumoto M, Ogihara T, NakagawaS, Omura T, Yonezawa A, Nakagawa T, Matsubara K. Schwann cell-derived CXCL1contributes to human immunodeficiency virus type 1 gp120-induced neuropathicpain by modulating macrophage infiltration in mice. Brain Behav Immun,88:325- 339 (2020)
  • Kusumoto J, Uda A, Kimura T, Furudoi S, Yoshii R, Matsumura M, Miyara T,AkashiM. Effect of educational intervention on the appropriate use of oral antimicrobials in oral and maxillofacial surgery: a retrospective secondary data analysis. BMC Oral Health, 21(1):20 (2021)
  • Uda A, Shigemura K, Kitagawa K, Osawa K, Onuma K, Yan Y, Nakano Y, NishiokaT, Fujisawa M, Yano I, Miyara T. Risk Factors for the Acquisition of Enterococcusfaecium Infection and Mortality in Patients with Enterococcal Bacteremia:A 5-year Retrospective Analysis in a Tertiary Care University Hospital.Antibiotics, 10(1)E64, (2021)
  • Yamamoto J, Omura T, Kasamo S, Yamamoto S, Kawata M, Yonezawa A, TarunoY, Endo H, Aizawa H, Sawamoto N, Matsubara K, Takahashi R, Tasaki Y. Impactof the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokineticsof L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.J Neural Transm (Vienna) , 128(1):27-36 (2021)
  • Morio K, Yamamoto K, Yano I. Relationship Between Tramadol Response and Cancer Cachexia: A Retrospective Cohort Study. Am J Hosp Palliat Care, 38(3):276- 282 (2021)
  • Yoshida A, Yamamoto K, Ishida T, Omura T, Itoh T, Nishigori C, Sakane T, Yano I. Sunitinib decreases the expression of KRT6A and SERPINB1 in 3D human epidermal models. Exp Dermatol, 30(3):337-346 (2021)
 

2019年度

  • Katada Y, Nakagawa S, Nishimura A, Sato YK, Taue H, Matsumura K, Yamazaki　K,Minakata K, Yano I, Omura T, Imai S, Yonezawa A, Sato Y, Nakagawa T,　MinatoyaK, Matsubara K.Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery.Eur J Clin Pharmacol, 75(4): 561-568(2019)
  • Yonezawa A, Otani Y, Kitano T, Mori M, Masui S, Isomoto Y, Tsuda M, ImaiS, Ikemi Y, Denda M, Sato Y, Nakagawa S, Omura T, Nakagawa T, Yano I, HayakariM, Takaori-Kondo A, Matsubara K.Concentration and glycoform of rituximab in plasma of patients with B-cellnon-Hodgkin’s lymphoma.Pharm Res, 36(6): 82(2019)
  • Yoshida M, Kojima H, Uda A, Haraguchi T, Ozeki M, Kawasaki I, Yamamoto K, Yano I, Hirai M, Uchida T.Bitterness-masking effects of different beverages on zopiclone and eszopiclone tablets.Chem Pharm Bull, 67 (5): 404-409 (2019)
  • Chayahara N, Mukohara T, Tachihara M, Fujishima Y, Fukunaga A, Washio K,Yamamoto M, Nakata K, Kobayashi K, Takenaka K, Toyoda M, Kiyota N, TobimatsuK, Doi H, Mizuta N, Marugami N, Kawaguchi A, Nishigori C, NishimuraY, MinamiH.Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal GrowthFactor Receptor-Induced Acne-Like Rash: A Randomized Left-Right ComparativeEvaluation (APPEARANCE).Oncologist, 24(7):885-e413(2019)
  • Itohara K, Yano I, Tsuzuki T, Uesugi M, Nakagawa S, Yonezawa A, OkajimaH, Kaido T, Uemoto S, Matsubara K.A Minimal PBPK Model for Tacrolimus in Living-Donor Liver Transplantation:Perspectives related to Liver Regeneration and CYP3A5 Genotype.CPT Pharmacometrics Syst Pharmacol, 8(8):587-595(2019)
  • Yamamoto K, Ioroi T, Harada K, Nishiyama S, Nishigori C, Yano I.Safety and efficacy of bis-glyceryl ascorbate (Amitose DGA) to prevent hand-foot skin reaction in patients with renal cell carcinoma receiving sunitinib therapy (DGAstudy): study protocol for a phase I/II, uncontrolled, single-arm, open-label trial.JMIR Res Protoc, 8(8):e14636 (2019)
  • Yamamoto K, Fukushima S, Mishima Y, Hashimoto M, Yamakawa K, Fujioka K,Iijima K, Yano I.Pharmacokinetic assessment of alprazolam-induced neonatal abstinence syndromeusing physiologically based pharmacokinetic model.Drug Metab Pharmacokinet, 34:400-402 (2019)
  • Uda A, Kimura T, Nishimura S, Ebisawa K, Ohji G, Kusuki M, Yahata M, IzutaR, Sakaue T, Nakamura T, Koike C, Tokimatsu I, Yano I, Iwata K, MiyaraT.Efficacy of educational intervention on reducing the inappropriate useof oral thirdgeneration cephalosporins.Infection, 47(6):1037-1045, 2019.
  • Uda A, Tokimatsu I, Osawa K, Shigemura K, Kimura T, Koike C, Nishioka T,Nakamura T, Yano I.Antibiotic de-escalation therapy in patients with communityacquired nonbacteremicpneumococcal pneumonia.Int J Clin Pharm, 41(6):1611-1617 (2019)
  • Kimura T, Ogura F, Kukita Y, Takahashi T, Yamamoto Y, Ioroi T, Yano I. Efficacy of pharmacists’ assessment and intervention based on ScreeningTool for Older Persons’ Appropriate Prescriptions for Japanese comparedwith Screening Tool for Older Persons’ Appropriate Prescriptions criteriaversion 2 in elderly patients with cardiovascular disease.Geriatrics Gerontology Int, 19(11):1101-1107 (2019)
  • Ogihara T, Nakagawa T, Hayashi M, Koyanagi M, Yonezawa A, Omura T, Nakagawa S, Kitada N, Imai S, Matsubara K.Improvement of peripheral vascular impairment by a phosphodiesterase type5 inhibitor tadalafil prevents oxaliplatininduced peripheral neuropathyin mice.J Pharmacol Sci,141 (4):131-138 (2019)
  • Negoro H, Goto T, Akamatsu S, Terada N, Kobayashi T, Matsui Y, YamamotoT, Omura T, Yonezawa A, Matsubara K, Ogawa O.Add-on effects of tadalafil in tamsulosin-treated patients with small benignprostatic enlargement: A randomized, placebo-controlled, double-blind,crossover study.Neurourol Urodynam, 39(1):237-242 (2020)
  • Fujiya M, Ueno N, Kashima S, Tanaka K, Sakatani A, Ando K, Moriichi K,Konishi H, Kamiyama N, Tasaki Y, Omura T, Matsubara K, Taruishi M, OkumuraT.Longchain polyphosphate is a potential agent for inducing mucosal healing of the colon in ulcerative colitis.Clin Pharmacol Ther, 107(2):452-461 (2020)
  • Zhang Y, Yonezawa A, Nakagawa S, Imai S, Denda M, Omura T, Nakagawa T, Matsubara K.Cisplatin, rather than oxaliplatin, increases paracellular permeability of LLC-PK1 cells via activating protein kinase C. Drug Metab Pharmacokinet.35(1):111-116 (2020)
  • Uda A, Shigemura K, Kitagawa K, Osawa K, Onuma K, Inoue S, Kotani J, Yan Y, Nakano Y, Nishioka T, Yano I, Miyara T, Fujisawa M.How does antimicrobial stewardship affect inappropriate antibiotic therapy in urological patients?Antibiotics, 9(2):63 (2020)
 

2018年度

  • Yoshimura K, Yano I, Yamamoto T, Kondo T, Kawanishi M, Isomoto Y, YonezawaA, Takaori-Kondo A, Matsubara KPharmacokinetic and pharmacodynamic markers of mycophenolic acid associatedwith effective prophylaxis for acute graft-versus-host disease and neutrophilengraftment in cord blood transplant patients.Biol Blood Marrow Transplant, 24(7):1441-1448 (2018)
  • Yamamoto K, Hara T, Nakagawa T, Hirai M, Miyake H, Fujisawa M, Yano IAssociation of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma.Target Oncol, 13(3):371-378 (2018)
  • Iwasaki M, Yano I, Fukatsu S, Hashi S, Yamamoto Y, Sugimoto M, Fukudo M,Masuda S, Nakagawa S, Yonezawa A, Kaido T, Uemoto S, Matsubara KPharmacokinetics and pharmacodynamics of once-daily tacrolimus comparedwith twice-daily tacrolimus in the early stage after living donor livertransplantation.Ther Drug Monit, 40(6):675-681 (2018)
  • Omura T, Sasaoka M, Hashimoto G, Imai S, Yamamoto J, Sato Y, Nakagawa S,Yonezawa A, Nakagawa T, Yano I, Tasaki Y, Matsubara KOxicam-derived non-steroidal anti-inflammatory drugs suppress 1-methyl-4-phenylpyridinium-induced cell death via repression of endoplasmic reticulum stressresponse and mitochondrial dysfunction in SH-SY5Y cells.Biochem Biophys Res Commun, 503(4):2963-2969, (2018)
  • Omura T, Matsuda H, Nomura L, Imai S, Denda M, Nakagawa S, Yonezawa A,Nakagawa T, Yano I, Matsubara KUbiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson’s disease.Biochem Biophys Res Commun, 506(3): 516-521 (2018).
  • Ito T, Yamamoto K, Ohsawa F, Otsuka I, Hishimoto A, Sora I, Hirai M, Yano IAssociation of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study.J Pharm Health Care Sci, 4:28 (2018)
  • Kitagawa K, Shigemura K, Yamamichi F, Osawa K, Uda A, Koike C, TokimatsuI, Shirakawa T, Miyara T, Fujisawa MBacteremia complicating urinary tract infection by Pseudomonas aeruginosa: Mortality risk factors.Int J Urol, 26(3):358-362 (2018)
  • Yokoyama N, Ishimura T, Oda T, Ogawa S, Yamamoto K, Fujisawa MAssociation of the PCK2 gene polymorphism with new-onset glucose intolerance in Japanese kidney transplant recipientsTransplant Proc, 50(4):1045-9 (2018)
 

2017年度

  • Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, YanoI, Minami H, HiraiM.Compatibility and stability of nab-paclitaxel in combination with otherdrugs.Kobe J Med Sci, 63(1): E9-E16 (2017)
  • Katada Y, Nakagawa S, Minakata K, Odaka M, Taue H, Sato Y, Yonezawa A,Kayano Y, Yano I, Nakatsu T, Sakamoto K, Uehara K, Sakaguchi H, YamazakiK, Minatoya K, Sakata R, Matsubara K.Efficacy of a protocol-based pharmacotherapy management on anticoagulationwith warfarin for patients with cardiovascular surgery.J Clin Pharmacol Ther, 42(5):591-597 (2017)
  • Yamamoto K, Shichiri H, Ishida T, Kaku K, Nishioka T, Kume M, MakimotoH, Nakagawa T, Hirano T, Bito T, Nishigori C, Yano I, Hirai M.Effects of ascorbyl-2-phosphate magnesium on human keratinocyte toxicityand pathological changes by sorafenib.Bio Pharm Bull, 40(9):1530-1536 (2017)
  • Hanai A, Ishiguro, H, Takashi. Sozu T, Tsuda M, Yano I, Nakagawa T, ImaiS, Hamabe Y, Toi M, Arai H, Tsuboyama T.Effects of cryotherapy on objective and subjective symptoms of paclitaxel-inducedneuropathy: Prospective self-controlled trial.J Natl Cancer Inst, 110(2): djx178 (2017)
  • Yoshimura K, Yano I, Yamamoto T, Kawanishi M, Isomoto Y, Yonezawa A, KondoT, Takaori-Kondo A, Matsubara K.Population pharmacokinetics and pharmacodynamics of mycophenolic acid usingthe prospective data in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant, 53(1):44-51 (2018).
  • Watanabe A, Yamamoto K, Ioroi T, Hirata S, Harada K, Miyake H, FujisawaM, Nakagawa T, Yano I, Hirai M.Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treatedwith Sunitinib: A Retrospective Analysis in Japanese Patients.Biol Pharm Bull, 40(4):458-464 (2017)
  • Shichiri H, Yamamoto K, Tokura M, Ishida T, Uda A, Bito T, Nishigori C,Nakagawa T, Hirano T, Yano I, Hirai M.Prostaglandin E1 reduces the keratinocyte toxicity of sorafenib by maintainingsignal transducer and activator of transcription 3 (STAT3) activity andenhancing the cAMP response element binding protein (CREB) activity.Biochem Biophys Res Commun, 485(2):227-233 (2017)
  • Ioroi T, Furukawa J, Kume M, Hirata S, Utsubo Y, Mizuta N, Miyake H, FujisawaM, Hirai M.Phase II study of palonosetron, aprepitant and dexamethasone to preventnausea and vomiting induced by multiple-day emetogenic chemotherapy.Support Care Cancer, doi: 10.1007/s00520-017-3967-2 (2017)
  • Kimura T, Uda A, Sakaue T, Yamashita K, Nishioka T, Nishimura S, EbisawaK, Nagata M, Ohji G, Nakamura T, Koike C, Kusuki M, Ioroi T, Mukai A, AbeY, Yoshida H, Hirai M, Arakawa S, Yano I, Iwata K, Tokimatsu I.Long-term efficacy of comprehensive multidisciplinary antibiotic stewardshipprograms centered on weekly prospective audit and feedback. Infection.doi:10.1007/s15010-017-1099-8 (2017)
 

2016年度

  • Ito S, Yano I, Hashi S, Tsuda M, Sugimoto M, Yonezawa A, Ikeda A, MatsubaraK.Population pharmacokinetic modeling of levetiracetam in pediatric and adultpatients with epilepsy by using routinely monitored data.Ther Drug Monit, 38(3):371-8 (2016)
  • Onoue H, Yano I, Tanaka A, Itohara K, Hanai A, Ishiguro H, Motohashi H, Masuda S, Matsubara K.Significant effect of age on docetaxel pharmacokinetics in Japanese femalebreast cancer patients by using the population modeling approach.Eur J Clin Pharmacol, 72(6):703-10 (2016)
  • Yoshimatsu H, Yonezawa A, Yamanishi K, Yao Y, Sugano K, Nakagawa S, ImaiS, Omura T, Nakagawa T, Yano I, Masuda S, Inui K, Matsubara K.Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiencyin mice.Sci Rep, 6:27557 (2016)
  • Zhou Z, Yano I, Odaka S., Morita Y, Shizuta S, Hayano M, Kimura T, AkaikeA, Inui K, Matsubara K.Effect of vitamin K2 on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data.J Pharm Health Care Sci , 2,17 (2016)
  • Tanaka A, Yano I, Shinsako K, Sato E, Fukudo M, Masuda S, Yamasaki T, KambaT, Ogawa O, Matsubara K.Population pharmacokinetics of everolimus in relation to clinical outcomesin patients with advanced renal cell carcinoma.Ther Drug Monit , 38:663-9 (2016)
  • Sato S, Jung H, Nakagawa T, Pawlosky R, Takeshima T, Lee WR, Sakiyama H, Laxman S, Wynn RM, Tu BP, MacMillan JB, De Brabander JK, Veech RL, Uyeda K.Metabolite Regulation of Nuclear Localization of Carbohydrate-responseElement-binding Protein (ChREBP): ROLE OF AMP AS AN ALLOSTERIC INHIBITOR. J Biol Chem , 291:10515-27 (2016)
  • Totsuka R, Kondo T, Matsubara S, Hirai M, Kurebayashi Y.Effects of VLA-1 Blockade on Experimental Inflammation in Mice.Kobe J Med Sci , 62(2):E27-37 (2016)
  • Mori H, Arita K, Yamaguchi T, Hirai M, Kurebayashi Y.Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-likeSkin Inflammation in Mice.Kobe J Med Sci, 62(4):E79-E88 (2016)
  • Nakamura T, Takahashi M, Niigata R, Yamashita K, Kume M, Hirai M, Yasui H.Changes in blood concentrations of trace metals in cancer patients receiving cisplatin-based chemotherapy.Biomed Rep. 5:737-744 (2016)
  • Kimura T, Ogura F, Yamamoto K, Uda A, Nishioka T, Kume M, Makimoto H, YanoI, Hirai M.Potentially inappropriate medications in elderly Japanese patients: effects of pharmacists’ assessment and intervention based on Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions criteria ver.2.J Clin Pharm Ther. 42:209-214 (2017)
  • Otani Y, Yonezawa A, Tsuda M, Imai S, Ikemi Y, Nakagawa S, Omura T, NakagawaT, Yano I, Matasubara K.Time-dependent structural alteration of rituximab analyzed by LC/TOF-MSafter a systemic administration to rats.PLoS One , 12(1):e0169588 (2017)
  • Takeuchi M, Yano I, Ito S, Sugimoto M, Yamamoto S, Yonezawa A, Ikeda A,Matsubara K.Population pharmacokinetics of topiramate in Japanese pediatric and adultpatients with epilepsy using routinely monitored data.Ther Drug Monit , 39:124-31 (2017)
  • Kawara F, Fujita T, Morita Y, Uda A, Masuda A, Saito M, Ooi M, Ishida T,Kondo Y, Yoshida S, Okuno T, Yano Y, Yoshida M, Kutsumi H, Hayakumo T,Yamashita K, Hirano T, Hirai M, Azuma T.Factors ssociated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.World J Gastroenterol , 23(11):2060-2067 (2017)
 

2015年度

  • Ioroi T, Kakuma T, Sakashita A, Miki Y, Ohtagaki K, Fujiwara Y, UtsuboY, Nishimura Y, Hirai M.Data analysis methods for assessing palliative care interventions in one-group pre?post studies.SAGE Open Medicine, 3:2050312115621313(2015)
  • Mizumoto A, Yamamoto K, Nakayama Y, Takara K, Nakagawa T, Hirano T, HiraiM.Induction of epithelial-mesenchymal transition via activation of epidermalgrowth factor receptor constitutes to sunitinib resistance in human renalcell carcinoma cell lines.J Pharmacol Exp Ther. 355(2):152-8 (2015)
  • Yamamoto K, Shichiri H, Uda A, Yamashita K, Nishioka T, Kume M, MakimotoH, Nakagawa T, Hirano T, Hirai M.Apoptotic Effects of the Extracts of Cordyceps militaris via Erk Phosphorylationin a Renal Cell Carcinoma Cell Line.Phytother Res. 29(5):707-13 (2015)
  • Yamamoto K, Ioroi T, Kanaya K, Shinomiya K, Komoto S, Hirata S, HaradaK, Watanabe A, Suno M, Nishioka T, Kume M, Makimoto H, Nakagawa T, HiranoT, Miyake H, Fujisawa M, Hirai M.STAT3 polymorphism rs4796793 may be a predictive factor of tumor responseto multiple tyrosine kinase inhibitors in metastatic renal cell carcinomain Japanese population.Med Oncol, 33(3):24 (2016)
  • Yamamoto K, Shinomiya K, Ioroi T, Hirata S, Harada K, Suno M, NishiokaT, Kume M, Makimoto H, Nakagawa T, Hirano T, Bito T, Nishigori C, MiyakeH, Fujisawa M, Hirai M.Association of single nucleotide polymorphisms in STAT3 with hand-footskin reactions in patients with metastatic renal cell carcinoma treatedwith multiple tyrosine kinase inhibitors: a retrospective analysis in Japanesepatients.Target Oncol. 11(1):93-9 (2016)
 

2014年度

 

2013年度

 

2012年度

 

2011年度

 

2010年度